Company Description
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally.
The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia.
In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.
The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2007 |
| IPO Date | Nov 2, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 3,930 |
| CEO | Phillip Frost |
Contact Details
Address: 4400 Biscayne Boulevard Miami, Florida 33137 United States | |
| Phone | 305 575 4100 |
| Website | opko.com |
Stock Details
| Ticker Symbol | OPK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000944809 |
| CUSIP Number | 68375N103 |
| ISIN Number | US68375N1037 |
| Employer ID | 75-2402409 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Charles W. Bishop | Chief Executive Officer of OPKO Renal |
| Dr. Phillip Frost Ph.D. | Chairman and Chief Executive Officer |
| Dr. Jane H. Hsiao M.B.A., Ph.D. | Vice Chairman and Chief Technical Officer |
| Dr. Elias Adam Zerhouni M.D. | President and Vice Chairman |
| Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer |
| Steven D. Rubin Esq., J.D. | Executive Vice President of Administration and Director |
| Dr. Akhtar Ashfaq FACP, FASN, M.D. | Senior Vice President of Clinical Research and Development and Medical Affairs - Opko Renal |
| Dr. Gary J. Nabel M.D., Ph.D. | Chief Innovation Officer and Director |
| Giovanni Abbadessa M.D., Ph.D. | Chief Medical Officer |
| Dr. Antonio F. Cruz | President of Transition Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 30, 2024 | DEFR14A | Filing |
| Aug 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 19, 2024 | 4 | Statement of changes in beneficial ownership of securities |